309345@2x.jpg

Real-world evidence: Flatiron Electronic Health Record Database study of EGFR TKIs

Erlotinib was the most widely prescribed first-line therapy for EGFR Mut+ NSCLC in this study, with similar efficacy observed for erlotinib- and afatinib-treated patients. The efficacy of EGFR TKIs observed in clinical studies was reflected in the real world setting.1

Study overview1

  •  This retrospective cohort analysis examined the management patterns and outcomes of patients with EGFR Mut+ NSCLC in a real-world setting, using data from the US Flatiron Electronic Health Record database.
page_36@2x.png

Key Results

page_37_1@2x.png

EGFR mutation test rate1

Rates of EGFR mutation testing increased from 2011until 2016.

page_37_2@2x.png

Usage frequency of different first-line therapies1

Erlotinib was the most widely prescribed therapy for first-line treatment of EGFR Mut+ NSCLC.

page_38_1@2x.png

Time to next treatment1

Patients receiving erlotinib or afatinib had longer time to next treatment than those receiving non-EGFR TKI therapy.

*Defined as all non-EGFR TKI treatments including chemotherapy and bevacizumab TTNT = time to next treatment

page_38_2@2x.png

Overall survival1

There were no significant differences in overall survival by treatment group.

*Defined as all non-EGFR TKI treatments including chemotherapy and bevacizumab